S&P 500   3,360.42 (+0.27%)
DOW   27,780.92 (+1.27%)
QQQ   269.94 (-0.56%)
AAPL   450.56 (+1.37%)
MSFT   206.94 (-2.61%)
FB   262.29 (-2.29%)
GOOGL   1,491.29 (-0.47%)
AMZN   3,133.94 (-1.06%)
NVDA   448.29 (+0.07%)
CGC   18.12 (+8.96%)
BABA   247.98 (-1.63%)
TSLA   1,418.93 (-2.33%)
MU   49.38 (+1.27%)
GE   6.67 (+4.22%)
AMD   82.50 (-2.77%)
T   30.17 (+0.50%)
F   7.08 (+3.21%)
ACB   10.23 (-0.39%)
GILD   68.33 (-1.47%)
NFLX   483.64 (-2.24%)
DIS   129.09 (-0.65%)
BAC   26.58 (+1.80%)
BA   178.41 (+4.93%)
S&P 500   3,360.42 (+0.27%)
DOW   27,780.92 (+1.27%)
QQQ   269.94 (-0.56%)
AAPL   450.56 (+1.37%)
MSFT   206.94 (-2.61%)
FB   262.29 (-2.29%)
GOOGL   1,491.29 (-0.47%)
AMZN   3,133.94 (-1.06%)
NVDA   448.29 (+0.07%)
CGC   18.12 (+8.96%)
BABA   247.98 (-1.63%)
TSLA   1,418.93 (-2.33%)
MU   49.38 (+1.27%)
GE   6.67 (+4.22%)
AMD   82.50 (-2.77%)
T   30.17 (+0.50%)
F   7.08 (+3.21%)
ACB   10.23 (-0.39%)
GILD   68.33 (-1.47%)
NFLX   483.64 (-2.24%)
DIS   129.09 (-0.65%)
BAC   26.58 (+1.80%)
BA   178.41 (+4.93%)
S&P 500   3,360.42 (+0.27%)
DOW   27,780.92 (+1.27%)
QQQ   269.94 (-0.56%)
AAPL   450.56 (+1.37%)
MSFT   206.94 (-2.61%)
FB   262.29 (-2.29%)
GOOGL   1,491.29 (-0.47%)
AMZN   3,133.94 (-1.06%)
NVDA   448.29 (+0.07%)
CGC   18.12 (+8.96%)
BABA   247.98 (-1.63%)
TSLA   1,418.93 (-2.33%)
MU   49.38 (+1.27%)
GE   6.67 (+4.22%)
AMD   82.50 (-2.77%)
T   30.17 (+0.50%)
F   7.08 (+3.21%)
ACB   10.23 (-0.39%)
GILD   68.33 (-1.47%)
NFLX   483.64 (-2.24%)
DIS   129.09 (-0.65%)
BAC   26.58 (+1.80%)
BA   178.41 (+4.93%)
S&P 500   3,360.42 (+0.27%)
DOW   27,780.92 (+1.27%)
QQQ   269.94 (-0.56%)
AAPL   450.56 (+1.37%)
MSFT   206.94 (-2.61%)
FB   262.29 (-2.29%)
GOOGL   1,491.29 (-0.47%)
AMZN   3,133.94 (-1.06%)
NVDA   448.29 (+0.07%)
CGC   18.12 (+8.96%)
BABA   247.98 (-1.63%)
TSLA   1,418.93 (-2.33%)
MU   49.38 (+1.27%)
GE   6.67 (+4.22%)
AMD   82.50 (-2.77%)
T   30.17 (+0.50%)
F   7.08 (+3.21%)
ACB   10.23 (-0.39%)
GILD   68.33 (-1.47%)
NFLX   483.64 (-2.24%)
DIS   129.09 (-0.65%)
BAC   26.58 (+1.80%)
BA   178.41 (+4.93%)
Log in

NASDAQ:ARWRArrowhead Pharmaceuticals Stock Price, Forecast & News

$40.31
+0.08 (+0.20 %)
(As of 08/10/2020 02:52 PM ET)
Add
Compare
Today's Range
$39.63
Now: $40.31
$40.73
50-Day Range
$36.72
MA: $44.31
$51.27
52-Week Range
$19.51
Now: $40.31
$73.72
Volume16,810 shs
Average Volume949,811 shs
Market Capitalization$4.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More
Arrowhead Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$168.80 million
Cash Flow$0.78 per share
Book Value$2.57 per share

Profitability

Net Income$67.97 million

Miscellaneous

Employees116
Market Cap$4.12 billion
Next Earnings Date11/23/2020 (Estimated)
OptionableOptionable
$40.31
+0.08 (+0.20 %)
(As of 08/10/2020 02:52 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARWR shares have increased by 41.1% and is now trading at $40.31.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Arrowhead Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arrowhead Pharmaceuticals
.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 19.75% and a negative return on equity of 5.65%.
View Arrowhead Pharmaceuticals' earnings history
.

What price target have analysts set for ARWR?

10 equities research analysts have issued 12 month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $62.00 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals
.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Press coverage about ARWR stock has been trending very positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Arrowhead Pharmaceuticals
.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Alliance Resource Partners (ARLP), Sasol (SSL), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.36%), Principal Financial Group Inc. (0.34%), Candriam Luxembourg S.C.A. (0.32%), Swiss National Bank (0.21%), Columbus Circle Investors (0.15%) and New York State Teachers Retirement System (0.14%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Mutual of America Capital Management LLC, Oak Ridge Investments LLC, First Trust Advisors LP, Nisa Investment Advisors LLC, Hancock Whitney Corp, Texas Permanent School Fund, and Strs Ohio. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Michael S Perry, and Patrick O'brien.
View insider buying and selling activity for Arrowhead Pharmaceuticals
.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was acquired by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Swiss National Bank, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Rafferty Asset Management LLC, New York State Teachers Retirement System, Vanguard Capital Wealth Advisors, and ProShare Advisors LLC.
View insider buying and selling activity for Arrowhead Pharmaceuticals
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $40.31.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $4.12 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.